At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
AZD1656 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Single-Blind, Placebo-Controlled, Phase IIA Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
In Brief
A Phase 2 clinical trial evaluating AZD1656 and Placebo for Type 2 Diabetes. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Metformin
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2009
First PostedJan 2009
Primary CompletionJul 2009
TodayJul 2026
First PostedJan 6, 2009
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.5 years ago
Interventions
AZD1656drug
Subjects will be treated with tolerable dose twice daily for another 24 days.
Placebodrug
Subjects will be treated with tolerable dose twice daily for another 24 days.